Have we improved in preventing and treating acute graft-versus-host disease?
- 1 November 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 18 (6) , 408-413
Abstract
Acute graft-versus-host disease (GVHD) is a considerable source of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Accordingly, progress in the prevention and primary therapy of this complication is needed to improve patient outcomes. Guided by insights into acute GVHD pathogenesis, investigators have explored novel cellular and pharmacologic approaches to acute GVHD prevention that demonstrates promise. Although pan-T-cell depletion has reduced GVHD, novel strategies that selectively deplete alloreactive T cells or modulate the balance of effector T cells and regulatory T cells offer promise to selectively abrogate acute GVHD while retaining protection from primary disease relapse and infectious complications. Divergent approaches in the primary therapy of acute GVHD have explored both combination approaches with standard dose glucocorticoids and additional immunosuppressive agents and conversely steroid-sparing approaches including topical agents such as beclomethasone or sirolimus as a steroid-free approach to acute GVHD therapy. Mature results of high-quality clinical trials are needed to determine the optimal therapy that results in effective control of the syndrome and limited toxicity. These complementary outcomes represent the therapeutic goal for future investigation in acute GVHD therapy.Keywords
This publication has 42 references indexed in Scilit:
- Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell–Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303Transplantation and Cellular Therapy, 2011
- T Cell–Depleted Unrelated Donor Stem Cell Transplantation Provides Favorable Disease-Free Survival for Adults with Hematologic MalignanciesTransplantation and Cellular Therapy, 2011
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseBlood, 2010
- A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimensBlood, 2010
- Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantationBone Marrow Transplantation, 2009
- Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials NetworkBlood, 2009
- Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomesBlood, 2009
- Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cellsBlood, 2008
- Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host diseaseBlood, 2008
- How I treat refractory acute GVHDBlood, 2007